Free Trial

Inozyme Pharma (INZY) Competitors

Inozyme Pharma logo
$4.00 0.00 (0.00%)
As of 07/1/2025

INZY vs. RCUS, DYN, SYRE, VERV, AVXL, MLYS, AVDL, NRIX, SANA, and LENZ

Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Spyre Therapeutics (SYRE), Verve Therapeutics (VERV), Anavex Life Sciences (AVXL), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Nurix Therapeutics (NRIX), Sana Biotechnology (SANA), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.

Inozyme Pharma vs. Its Competitors

Arcus Biosciences (NYSE:RCUS) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Inozyme Pharma has lower revenue, but higher earnings than Arcus Biosciences. Inozyme Pharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$258M3.76-$283M-$4.19-2.18
Inozyme PharmaN/AN/A-$102.02M-$1.69-2.37

Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.

Arcus Biosciences currently has a consensus target price of $21.29, suggesting a potential upside of 132.63%. Inozyme Pharma has a consensus target price of $11.75, suggesting a potential upside of 193.75%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89
Inozyme Pharma
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44

Inozyme Pharma has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Arcus Biosciences' return on equity of -70.58% beat Inozyme Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-258.94% -70.58% -32.97%
Inozyme Pharma N/A -159.93%-82.48%

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 12.2% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Arcus Biosciences had 3 more articles in the media than Inozyme Pharma. MarketBeat recorded 3 mentions for Arcus Biosciences and 0 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 1.87 beat Arcus Biosciences' score of -0.14 indicating that Inozyme Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Arcus Biosciences Neutral
Inozyme Pharma Very Positive

Summary

Arcus Biosciences beats Inozyme Pharma on 9 of the 16 factors compared between the two stocks.

Get Inozyme Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INZY vs. The Competition

MetricInozyme PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$258.25M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-2.378.2821.0120.09
Price / SalesN/A303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book4.447.678.125.65
Net Income-$102.02M-$55.28M$3.25B$257.91M
7 Day PerformanceN/A2.50%0.97%2.09%
1 Month Performance0.50%11.70%7.36%11.13%
1 Year Performance-24.81%4.89%31.31%18.40%

Inozyme Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INZY
Inozyme Pharma
3.5236 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750Positive News
RCUS
Arcus Biosciences
2.3406 of 5 stars
$9.66
+3.5%
$21.29
+120.5%
-39.0%$1.02B$258M-2.30500
DYN
Dyne Therapeutics
3.8968 of 5 stars
$8.91
+3.1%
$41.13
+361.6%
-77.3%$1.01BN/A-2.48100Analyst Forecast
Insider Trade
SYRE
Spyre Therapeutics
1.9298 of 5 stars
$16.41
+4.6%
$53.40
+225.4%
-46.2%$989.20M$890K-4.3573
VERV
Verve Therapeutics
2.8995 of 5 stars
$11.03
flat
$14.57
+32.1%
+45.8%$983.25M$59.61M-5.23110
AVXL
Anavex Life Sciences
3.924 of 5 stars
$11.48
+3.3%
$44.00
+283.3%
+86.8%$980.05MN/A-20.8740
MLYS
Mineralys Therapeutics
2.2236 of 5 stars
$15.02
+3.7%
$32.25
+114.7%
+3.2%$979.00MN/A-4.0328Insider Trade
AVDL
Avadel Pharmaceuticals
1.8367 of 5 stars
$10.04
+4.5%
$18.17
+80.9%
-33.4%$971.26M$194.45M-37.1970Analyst Forecast
NRIX
Nurix Therapeutics
2.4806 of 5 stars
$12.69
+2.0%
$29.47
+132.2%
-44.5%$970.15M$54.55M-4.86300Analyst Forecast
Analyst Revision
SANA
Sana Biotechnology
3.2939 of 5 stars
$4.22
+1.0%
$9.17
+117.2%
-30.3%$951.51MN/A-4.80380Positive News
Gap Up
LENZ
LENZ Therapeutics
1.3396 of 5 stars
$33.73
-2.8%
$46.60
+38.2%
+58.5%$949.37MN/A-19.06110

Related Companies and Tools


This page (NASDAQ:INZY) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners